MilliporeSigma, a Life Science and High Technology company, has extended its ongoing collaboration with Baylor College of Medicine, it was reported on Wednesday.
The collaboration has been extended to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase one clinical trials.
The partnership is intended to improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016. The companies will also develop a new manufacturing platform for a second Covid-19 vaccine candidate to reduce the time to enter into Phase one clinical trials. The aim of the partnership is to develop a suitable manufacturing process and steps that lead to a scale-up approach suitable for pilot and later industrial production.
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Bio-Techne expands COMET spatial biology platform with new SPYRE Panels and Amplification Kits
CRISM Therapeutics advances Phase 2 glioblastoma trial with initial ChemoSeed batch manufactured
Myosin Therapeutics granted USD2m funding from Florida Department of Health
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets